New hope for tough myeloma: early trial of BP2202 begins
NCT ID NCT07667868
First seen Jun 27, 2026 · Last updated Aug 11, 2026 · Updated 4 times
Summary
This early-stage trial is testing a new drug called BP2202 in 24 people with multiple myeloma that has come back or no longer responds to standard treatments. The main goal is to see if BP2202 is safe and to find the best dose. Researchers will also watch for any signs that the drug is shrinking the cancer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BP2202 (a biological drug given by IV infusion)
- What this could lead to
- If this early trial shows BP2202 is safe and works, it could point toward a new treatment option for people with multiple myeloma that has come back or stopped responding to other therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 24 participants, so it is mainly checking safety, not effectiveness. The drug may not work well enough to move forward, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Pre-Dose prevent a dangerous reaction in multiple myeloma treatment?
- New drug combo aims to tackle Hard-to-Treat myeloma
- New hope for myeloma patients: epunamin combo under study
- New combo therapy aims to tackle Hard-to-Treat myeloma
- New drug duo aims to tackle Hard-to-Treat myeloma
- New combo attack on hard-to-treat myeloma enters human testing